Current pharmacotherapy of amebiasis, advances in new drugs, and design of a vaccine;Farmacoterapia actual de la amibiasis, avances en nuevas drogas y diseño de una vacuna

Investigacion Clinica (Venezuela)

Volumn 53, Issue 3, 2012, Pages 301-314

  Chacín Bonilla, Leonor ^a,b  

^a Instituto de Investigaciones Clínicas 'Dr Américo Negrette'   (Venezuela)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Amebiasis; Amebicides; Entamoeba histolytica; Treatment; Vaccine

Indexed keywords

METRONIDAZOLE; NITAZOXANIDE; NITROIMIDAZOLE; PAROMOMYCIN; ANTIAMEBIC AGENT; VACCINE;

AMEBIASIS; ARTICLE; DRUG DESIGN; ENTAMOEBA HISTOLYTICA; HUMAN; INTESTINE PARASITE; MORBIDITY; MORTALITY; REVIEW;

AMEBIASIS; AMEBICIDES; DRUG DESIGN; HUMANS; VACCINES;

EID: 84872679301     PISSN: 05355133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Ali IKM, Clark CG, Petri WA Jr. Molecular epidemiology of amebiasis. Infect Genet Evol 2008; 8: 698-707.
2. Chacín-Bonilla L. Amibiasis: Implicaciones del reconocimiento de Entamoeba dispar e identificación de Entamoeba moshkovskii en humanos. Inv Clin 2010; 51: 239-256.
3. Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003; 16: 713-729.
4. Walsh JA. Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Rev Infect Dis 1986; 8: 228-238.
5. Jackson TF. Entamoeba histolytica and Entamoeba dispar are distinct species; clinical, epidemiological, and serological evidence. Int J Parasitol 1998; 28: 181-186.
6. Caballero-Salcedo A, Viveros-Rogel M, Salvatierra B, Tapia-Conyer R, Sepúlveda-Amor J, Gutiérrez G. Seroepidemiology of amebiasis in México. Am J Trop Med Hyg 1994; 50: 412-419.
7. Chacín-Bonilla L, Bonpart D. A seroepidemiological study of amebiasis in adults in Venezuela. Am J Trop Med Hyg 1981; 30: 1201-1205.
8. Chacín-Bonilla L, Chacín-Martinez E, Espinoza E, Cárdenas B. A seroepidemiological study of amebiasis in children of low socioeconomic level in Maracaibo, Venezuela. Am J Trop Med Hyg 1982; 31: 1103-1106.
9. Chacín-Bonilla L, Mathews HM, Healy GR, Dikdan Y, Rodríguez-Zambrano N. Serologic and parasitological studies of amebiasis in two suburban communities of Maracaibo, Venezuela. Invest Clin 1984; 25: 69-80
10. Chacín-Bonilla L, Mathews HM, Dikdan Y, Guanipa N. Estudio seroepidemiológico de la amibiasis en una comunidad del estado Zulia, Venezuela. Rev Inst Med Trop Sao Paulo 1990; 32: 467-473.
11. Braga LL, Lima AM, Sears CL, Newman RD, Wuhib T, Paiva CA, Guerrant RL, Mann BJ. Seroepidemiology of Entamoeba histolytica in a slum in northeastern Brazil. Am J Trop Med Hyg 1996; 55: 693-697.
12. Petri WA Jr, Mondal D, Peterson KM, Duggal P, Haque R. Association of malnutrition with amebiasis. Nutr Rev 2009; 67(Suppl.2): S207-S215.
13. Stauffer W, Abd-Alla M, Ravdin JI. Prevalence and incidence of Entamoeba histolytica infection in South Africa and Egypt. Arch Med Res 2006; 37: 266-269.
14. Knight R. The chemotherapy of amoebiasis. J Antimicrobial Chemotherapy 1980; 6: 577-593.
15. Powel SJ, MacLeod IN, Wilmot AJ, Elsdon-Dew R. Metronidazole in amoebic dysentery and amoebic liver abscess. Lancet 1966; ii: 1329-1331.
16. Purohit V, Basu AK. Mutagenicity of nitroaromatic compounds. Chem Res Toxicol 2000; 13: 673-692.
17. López Nigro MM, Palermo AM, Mudry MD, Carballo MA. Cytogenetic evaluation of two nitroimidazole derivatives. Toxicol In Vitro 2003; 17: 35-40.
18. El-Nahas FA, El-Ashmawy MI. Reproductive and cytogenetic toxicity of metronidazole in male mice. Basic Clin Pharmacol Toxicol 2004; 94: 226-231.
19. Escobedo AA, Cimerman S. Giardiasis: a pharmacotherapy review. Expert Opin Pharmacother 2007; 8: 1885-1902.
20. Fujishima T, Nishise S, Ichihara M, Kobayashi S, Takeuchi T. Difficulties in the treatment of intestinal amoebiasis in mentally disabled individuals at a rehabilitation institution for the intellectually impaired in Japan. Chemotherapy 2010; 56: 348-352.
21. Botero DA, Restrepo M. Parasitosis humana. 2nd Ed. Bogotá (Colombia): Editorial Presencia Ltda; 1992; p 25-54.
22. Petri WA Jr. Therapy of intestinal protozoa. Trends Parasitol 2003; 19: 523-526.
23. Bobbi S, Pritt MD, Clark G. Amebiasis. Mayo Clin Proc 2008; 83: 1154-1160.
24. Salles JM, Moraes LA, Salles MC. Hepatic amebiasis. Braz J Infect Dis 2003; 7: 96-110.
25. Blessmann J, Tannich E. Treatment of asymptomatic intestinal Entamoeba histolytica infection. N Engl J Med 2002; 347: 1384.
26. WHO/PAHO/UNESCO. A consultation with experts on amoebiasis. Epidemiol Bull 1997; 18: 13-14.
27. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 2001; 63: 186-192.
28. Holtan NR. Giardiasis. A crimp in the life-style of campers, travelers, and others. Postgrad Med 1988; 83: 54-61.
29. Haghihgi A, Kobayashi S, Takeuchi T; Thammapalerd N; Nozaki T. Geographic diversity among genotypes of Entamoeba histolytica field isolates. J Clin Microbiol 2003; 4: 3748-3756.
30. Morán P, Gómez A, Valadez A, García G, Ramos F, González E, Limón A, Riebeling C, Valenzuela O, Rojas L, Melendro EI, Ximénez C. Periodicity and patterns of Entamoeba histolytica and Entamoeba dispar infection in HIV+/AIDS patients in Mexico. Ann Trop Med Parasitol 2009; 103: 307-315.
31. Beaver PC, Jung RC, Cupp EW. Parasitología Clínica. 2nd Ed. Barcelona (España): Editores Salvat; 1986, p 114-139.
32. Chacín-Bonilla L. Diagnóstico microscópico de amibiasis: Método obsoleto pero necesario en el mundo en desarrollo. Invest Clin 2011; 52: 291-294.
33. Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 2002; 18: 95-97.
34. Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother 2002; 49: 103-111.
35. Cedillo-Rivera R, Chávez B, González-Robles A, Tapia A, Yepez-Mulia L. In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites. J Eukaryot Microbiol 2002; 49: 201-208.
36. Romero Cabello R, Robert Guerrero L, Muñoz García M del R, Geyne Cruz A. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in México. Trans R Soc Trop Med Hyg 1997; 91: 701-703.
37. Abaza H, El-Zayadi AR, Kabil SM, Rizk H. Nitazoxanide in the treatment of patients with intestinal protozoan and helminthic infections: a report on 546 patients in Egypt. Curr Ther Res 1998; 59: 116-121.
38. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or Entamoeba dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184: 381-384.
39. Rossignol JF, Kabil SM, El Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007; 101: 1025-1031.
40. Stockis A, Allemon AM, De Bruyn S, Gengler C. Nitazoxanide pharmacokinetics and tolerability in man after single ascending doses. Int J Clin Pharmacol Ther 2002; 40: 213-220.
41. Irfan I, Sawangjaroen N, Bhat AR, Azam A. New dioxazole derivatives: Synthesis and effects on the growth of Entamoeba histolytica and Giardia intestinalis. Eur J Med Chem 2010; 45: 1648-1653.
42. Hayat F, Salahuddin A, Zargan J, Azam A. Synthesis, characterization, antiamoebic activity and cytotoxicity of novel 2-(quinolin-8-yloxy) acetohydrazones and their cyclized products (1,2,3-thiadiazole and 1,2,3-selenadiazole derivatives). Eur J Med Chem 2010; 45: 6127-6134.
43. López-Vallejo F, Castillo R, Yépez-Mulia L, Medina-Franco JL. Benzotriazoles and indazoles are scaffolds with biological activity against Entamoeba histolytica. J Biomol Screen 2011; 16: 862-868.
44. Heredia-Rojas JA, Torres-Flores AC, Rodríguez-De la Fuente AO, Mata-Cárdenas BD, Rodríguez-Flores LE, Barrón-González MP, Torres-Pantoja AC, Alcocer-González JM. Entamoeba histolytica and Trichomonas vaginalis: Trophozoite growth inhibition by metronidazole electro-transferred water. Exp Parasitol 2011; 127: 80-83.
45. Navarrete-Vázquez G, Chávez-Silva F, Argotte-Ramos R, Rodríguez-Gutiérrez M del C, Chan-Bacab MJ, Cedillo-Rivera R, Moo-Puc R, Hernández-Nuñez E. Synthesis of benzologues of nitazoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity. Bioorg Med Chem Lett 2011; 21: 3168-3171.
46. Chaudhry OA, Petri WA Jr. Vaccine prospects for amebiasis. Expert Rev Vaccines 2005; 4: 657-668.
47. Stanley SL Jr. Vaccines for amoebiasis: barriers and opportunities. Parasitology 2006; 133 (Suppl.): S 81-86.
48. Ralston KS, Petri WA Jr. Tissue destruction and invasion by Entamoeba histolytica. Trends Parasitol 2011; 27: 253-262.
49. Bethony JM, Cole RN, Guo X, Kamhawi S, Lightowlers MW, Loukas A, Petri W, Reed S, Valenzuela JG, Hotez PJ. Vaccines to combat the neglected tropical diseases. Immunol Rev 2010; 239: 237-270.
50. Guo X, Barroso L, Becker SM, Lyerly DM, Vedvick TS, Reed SG, Petri WA Jr, Houpt ER. Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon. Infect Immun 2009; 77: 3909-3918.
51. Guo X, Barroso L, Lyerly DM, Petri WA Jr, Houpt ER. CD4+ and CD8+ T celland IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine. Vaccine 2011; 29: 772-777.
52. Carrero JC, Contreras Rojas A, Sánchez-Hernández B, Petrosyan P, Bobes RJ, Ortiz-Ortiz L, Laclette JP. Protection against murine intestinal amoebiasis induced by oral immunization with the 29kDa antigen of Entamoeba histolytica and cholera toxin. Exp Parasitol 2010; 126: 359-365.
53. Lotter H, Russmann H, Heesemann J, Tannich E. Attenuated recombinant Yersinia as live oral vaccine carrier to protect against amoebiasis. Int J Med Microbiol 2008; 298: 79-86.
54. Meneses-Ruiz DM, Laclette JP, Aguilar-Díaz H, Hernández-Ruiz J, Luz-Madrigal A, Sampieri A, Vaca L, Carrero JC. Mucosal delivery of ACNPV baculovirus driving expression of the gal-lectin LC3 fragment confers protection against amoebic liver abscess in hamster. Int J Biol Sci 2011; 7: 1345-1356.
55. Shoji I, Aizaki H, Tani H, Ishii K, Chiba T, Saito I, Miyamura T, Matsuura Y. Efficient gene transfer into various mammalian cells, including non-hepatic cells, by bac-ulovirus vectors. J Gen Virol 1997; 78: 2657-2664.